Dr. Soergel joins Madrigal from Novartis, where he served as EVP and Global Head of Cardiovascular, Renal, and Metabolism Development, overseeing 10 late-stage development programs in 2024. He led teams advancing Entresto's indications and brought novel medicines to approval including Leqvio, Fabhalta, and Vanrafia, while serving as development lead for the acquisitions of the Medicines Company and Chinook Therapeutics. Prior to Novartis, he served as SVP of Clinical Development and CMO at Trevena, and began his career in early-stage clinical development at GlaxoSmithKline.